ORIGINAL RESEARCH article
Front. Pediatr.
Sec. Pediatric Pulmonology
Volume 13 - 2025 | doi: 10.3389/fped.2025.1642786
Comparison of the efficacy of aerosolized inhalation of different doses of recombinant human interferon alpha1b combined with budesonide in the treatment of asthmatic bronchitis in children
Provisionally accepted
- Longquanyi District of Chengdu Maternity & Child Health Care Hospital, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Asthmatic Bronchitis (AB) is the most common type of bronchitis in children, severely affecting their quality of life and growth. This study aimed to investigate the efficacy and safety of aerosol inhalation of different doses of Recombinant Human Interferon alpha1b (IFNα1b) combined with budesonide in treating childhood AB. Methods: This was a retrospective cohort study. A total of 150 children with AB treated in our hospital from December 2022 to January 2025 were retrospectively screened. They were divided into three groups based on treatment protocols: control group (budesonide alone), low-dose group (2.0 µg/kg IFNα1b + budesonide), and high-dose group (3.0 µg/kg IFNα1b + budesonide). The three groups were matched 1:1:1 by gender, age, disease duration, and allergy history. The primary outcomes were the remission time of cough, wheezing, and pulmonary rales. The secondary outcomes included improvements in pulmonary function indices, changes in immunoglobulin levels, and adverse events. Results: After treatment, the remission times of cough, wheezing, and pulmonary rales in the high-dose group were significantly shorter than those in the low-dose and control groups, and the low-dose group was significantly shorter than the control group (all p < 0.05). The high-dose group showed significantly better improvements in pulmonary function and immunoglobulin levels than the control and low-dose groups, and the low-dose group also outperformed the control group (all p < 0.05). There were no significant differences in adverse events among the three groups (p <0.05). Conclusion: High-dose (3.0 µg/kg) IFNα1b combined with budesonide has certain advantages in improving cough, wheezing, pulmonary rales, pulmonary function, and immune status in children with AB, providing new clinical references for treatment.
Keywords: Asthmatic bronchitis, Bronchitis, Children, recombinant human interferon alpha1b, Budesonide
Received: 07 Jun 2025; Accepted: 15 Sep 2025.
Copyright: © 2025 Huang, Lei, Zhang, Chen, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Delian Li, delian20250601@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.